Gilead Sciences’ stock surged more than 8% on Friday, as its latest earnings drew the consensus from Wall Street that the company’s HIV franchise is not only holding firm but expanding, with its new prevention drug Yeztugo poised to be a catalyst for future growth. Analysts from leading firms upgraded…
Shares of genetic testing company Natera (NASDAQ:NTRA) jumped sharply in morning trading, rising as much as 17% after the…
Firefly Aerospace made a powerful entrance to the public markets on Thursday, surging more than 50% in its Nasdaq…
Goldman Sachs analyst Asad Haider says investors are overreacting to the late-stage data Eli Lilly & Co (NYSE: LLY)…
The FTSE 100 Index pulled back this week as many British companies like Intercontinental Hotels, Legal & General, BP,…
Asian stock markets rose on Friday, with a powerful rally in Japanese shares leading the way, as investors reacted…
India’s domestic institutional investors stepped in with their largest purchase of local stocks in four months on Thursday, providing…
European stock markets began Friday’s session with a mixed and somewhat hesitant performance, as a sharp drop in shares…
Novo Nordisk shares rose over 5% in morning trade on Friday, ranking among the top gainers on the STOXX…